SAN FRANCISCO, CA, Privately-held biopharmaceutical company focused on advancing best-in-class medicines in immunology, autoimmune diseases, and oncology, announced that it successfully met its milestone obligations and received its second tranche of funding totaling $12.5 million in July 2012.
Read More